

How I Treat and Design Studies for Fibrosis related to Chronic GVHD

Stephanie J. Lee

Clinical Research Division, Fred Hutchinson Cancer Center

Aim/Introduction:

In this small group open discussion session, we plan to discuss treatment options and study design considerations for fibrosis related to chronic GVHD. We will start with 2-3 cases from the audience to review current treatment options, followed by a conversation about study design considerations for potential new treatments for fibrotic chronic GVHD.

Expert

Name/title: Stephanie Lee / Professor

Affiliation(s): Fred Hutchinson Cancer Center

Brief self-introduction:

Dr. Stephanie Lee is a Professor at the Fred Hutchinson Cancer Center and the University of Washington, Seattle, WA and the David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research. Her research focuses on outcomes after hematopoietic cell transplantation, with a particular emphasis on chronic graft-versus-host disease.

Related publications:

- 1) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. *N Eng J Med* 2021; 382: 228-238.
- 2) Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study. *J Clin Oncol* 2022; in press
- 3) Three FDA-approved therapies for chronic GVHD. *Blood* 2022; 139: 1642-1645.

Facilitator

Name/title: Yoshihiro Inamoto / Inpatient Medical Director

Affiliation: National Cancer Center Hospital

Brief self-introduction:

Dr. Inamoto graduated from Nagoya University, was trained in the Long-Term Follow Up program at the Fred Hutchinson Cancer Research Center and is currently a HCT Inpatient Medical Director at the National Cancer Center Hospital in Japan. His major research themes include GVHD, late effects and immunology after HCT.

Related publications:

- 1) Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. *Blood*. 2013;121:5098-5103.
- 2) Failure-free survival after initial systemic treatment of chronic graft-versus host disease. *Blood* 2014;124:1363-1371.
- 3) Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. *Blood Adv.* 2019; 24; 3: 2764-2777.